NASDAQ:ALIM
Alimera Sciences Stock News
$3.90
+0.0300 (+0.775%)
At Close: Mar 27, 2024
Alimera Sciences, Inc. Discusses Its 2021 Global Expansion Strategy with The Stock Day Podcast
09:05am, Monday, 01'st Feb 2021
Phoenix, Arizona--(Newsfile Corp. - February 1, 2021) - The Stock Day Podcast welcomed Alimera Sciences, Inc. (NASDAQ: ALIM) ("the Company"), a pharmaceutical company that specializes in the commercia
Alimera Sciences Announces Preliminary Top-line Results for Fourth Quarter and Full-Year 2020
08:00am, Tuesday, 19'th Jan 2021
ATLANTA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription op
Alimera Sciences to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference
08:00am, Tuesday, 05'th Jan 2021
ATLANTA, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the managemen
Alimera Sciences Announces Launch of ILUVIEN® in the Netherlands
08:30am, Wednesday, 09'th Dec 2020
ILUVIEN has been launched for both Diabetic Macular Edema and Non-Infectious Posterior Uveitis Indications ILUVIEN has been launched for both Diabetic Macular Edema and Non-Infectious Posterior Uveiti
Alimera Sciences to Present at the 13th Annual LD Micro Main Event Virtual Conference
08:30am, Tuesday, 08'th Dec 2020
ATLANTA, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the managemen
Alimera Sciences Announces Participation at the 11th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 17, 2020
08:00am, Monday, 16'th Nov 2020
ATLANTA, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the managemen
Alimera Sciences Announces Third Quarter 2020 Financial Results
04:05pm, Wednesday, 28'th Oct 2020
Rebound Continues from COVID Challenges Rebound Continues from COVID Challenges
Trump's New Iran Sanctions Might Not Kill the Nuclear Deal, But They Will Hurt the U.N.
01:31pm, Wednesday, 19'th Aug 2020
Secretary of State Mike Pompeo is reportedly heading to New York to invoke 'snapback' provisions of the Iran nuclear deal. It's an act of diplomatic vandalism.
Alimera Sciences Signs Distribution Agreement With Nordic Prime to Expand International Sales of ILUVIEN® Into Nordic Countries
12:00pm, Thursday, 13'th Aug 2020
ATLANTA, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmi
Up to 750,000 UK Covid test kits recalled due to safety concerns
11:11am, Saturday, 08'th Aug 2020
Products made by diagnostics firm Randox removed from care homes and individuals
Abu Dhabi's Etihad Airways posts $758M in half-year losses
11:42am, Thursday, 06'th Aug 2020
Abu Dhabi’s Etihad Airways says core operating losses amounted to $758 million for the first half of the year, driven by a nearly 40% drop in revenue due in part to the impact of the coronavirus pan
What Makes Alimera Sciences (ALIM) a New Strong Buy Stock
04:00pm, Wednesday, 05'th Aug 2020
Alimera Sciences (ALIM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
New Strong Buy Stocks For August 5th
03:44pm, Wednesday, 05'th Aug 2020
New Strong Buy Stocks For August 5th
LD Micro Announces Preliminary List of Presenters for the LD 500
01:00pm, Wednesday, 05'th Aug 2020
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively onlin
MyoKardia Heart Trial, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:MYOK)
03:41pm, Tuesday, 04'th Aug 2020
MyoKardia reports initiating trial for invasive septal reduction therapy. Aileron completes enrollment in chemotherapeutic agent trial.